VPT:CC - Ventripoint Announces Sponsorship for the 2022 SickKids Echo Symposium
(TheNewswire)
Toronto, Ontario – TheNewswire –May 3, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that it will be a sponsorfor the 2022 SickKids Echo Symposium. The topic of this year’ssymposium is introduction to cardiac anatomical (morphological)abnormalities in congenital heart disease, how it relates toechocardiographic imaging, and the use of echocardiographic imaging insurgical decision-making in congenital heart disease. The event willtake place May 6-8 at the Hospital for Sick Children in Toronto,Ontario. There is expected to be 2000+ attendees.
The 2022 SickKids Symposium aims to improve theknowledge of physicians, surgeons, and sonographers who useechocardiograms in newborn and paediatric patient populations orechocardiographic studies in adults with repaired congenital heartdisease. This multi-day event will have educational presentations,discussions, and live scanning that focus on the relationship betweencardiac morphology and echocardiographic imaging.
As a sponsor for the event, Ventripoint’s logo willbe displayed on the conference website and on-screen during scheduledbreaks during the weekend courses. There will be an in-person demo ofthe VMS+, followed by a period for questions about the VMS+ system.This is an excellent opportunity for Ventripoint to educate conferenceattendees about the capabilities of the VMS+ system, as well asfurther exposure for those not yet familiar with the system.
Ventripoint is committed to developing cardiacdiagnostic tools that provide accurate and reliable measurements ofcardiac function. Ventripoint’s involvement in the 2022 SickKidsSymposium highlights the commitment to supporting effective clinicalassessment and diagnosis through education and promotion.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.